Arrowstreet Capital
PRQR icon

Arrowstreet Capital’s ProQR Therapeutics PRQR Stock Holding History

Arrowstreet Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-42,947
Closed -$426K – 2065
2019
Q4 		$426K Buy
+42,947
New +$335K ﹤0.01% 1522

Other funds holding PRQR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Arrowstreet Capital's PRQR Position: Q1 2020 in Review

Arrowstreet Capital sold out of ProQR Therapeutics (PRQR) in Q1 2020, closing a stake of 42,947 shares — an estimated $426K sold.

Arrowstreet Capital first reported a position in PRQR in Q4 2019 and held it in 1 quarter. The position peaked at $426K in Q4 2019. 44 funds tracked by Wall St. Rank hold PRQR as of Q1 2020.

  • Arrowstreet Capital reported no remaining ProQR Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 42,947 ProQR Therapeutics shares in Q1 2020, an estimated $426K.
  • Arrowstreet Capital first reported a position in ProQR Therapeutics in Q4 2019 and held it in 1 quarter.
  • Arrowstreet Capital's ProQR Therapeutics position peaked at $426K in Q4 2019.
  • 44 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2020.

Based on Arrowstreet Capital's 13F filing for Q1 2020, filed 15 May 2020.